Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

HealthDay News — Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a study published online in the July issue of The Lancet ...

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid ...

Novartis’ Kisqali (ribociclib) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Patrick Maxwell, Regius Professor of Physic and Head of the School of Clinical Medicine at the University of Cambridge, UK ...

Over thirty promising, young Utrecht researchers will receive a Veni grant of up to 320,000 euros from the Dutch Research Council (NWO). 1 in 7 Venis went to Utrecht researchers this year.

Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

We need to move beyond the lump in our awareness. Not all skin changes, discharges, or pain means breast cancer ...